Trial
NCT04880109
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Aptabio Therapeutics, Inc.
Collaborators
Covance
Condition
COVID-19
Intervention
APX-115
Why stopped
Enrollment Challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-10